Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Brain Neoplasms 2Small Cell Lung Carcinoma 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Glutamine 2sagopilone 1nicotinamide-beta-riboside 1allantoicase 1Vitamin D 1Vitamin B 6 1Vitamin B 12 1Taxoids 1Tadalafil 1Sirolimus 1Prednisolone 1Paclitaxel 1Minocycline 1Metformin 1Losartan 1Hydroxychloroquine 1G(M1) Ganglioside 1Fatty Acids, Omega-3 1Exercise 1Everolimus 1Etoricoxib 1Ethosuximide 1Epoetin Alfa 1Dietary Supplements 1Dexamethasone 1Cryotherapy 1Bortezomib 1BID protein, human 1Acupuncture Therapy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × sagopilone × Clear all
NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Bayer

Phase 2 Completed
150 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡